8 November 2012 -
ThromboGenics (Heverlee, Belgium) announces Business Update Q3 - The Company reported revenues of 75.1 million EUR in the first nine months of 2012 versus €2.5 million in the first nine months of 2011. The revenues in 2012 are almost entirely due to the upfront payment from Alcon.
In March, ThromboGenics raised 77.8 million EUR in a private placement
Thrombogenics.com
No comments:
Post a Comment